2012 Annual Report – DTR 6.3.5 Disclosure
2012 Annual Report – DTR 6.3.5 Disclosure
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that the following documents have today been posted or otherwise made available to shareholders:
- 2012 Annual Report and Accounts
- Form of Proxy
In accordance with Listing Rule 9.6.1, a copy of each of these documents has been uploaded to the National Storage Mechanism and will be available for viewing shortly.
The 2012 Annual Report and Accounts and Notice of the 2013 Annual General Meeting are also available on Shire’s website at www.shire.com.
Disclosure & Transparency Rule (“DTR”) 6.3.5 requires the Company to disclose to the media certain information from its Annual Report, if that information is of a type that would be required to be disseminated in a half-yearly report. Accordingly, the Appendix to this announcement contains a management report and the directors’ responsibility statement. It should be read in conjunction with the Company’s unaudited full year results for the year ended December 31, 2012, issued on February 14, 2013 which comprises the Company’s consolidated financial statements prepared under U.S. GAAP. The Appendix together with the unaudited full year results constitute the material required by DTR 6.3.5 to be communicated to the media in unedited full text through a Regulated Information Service. This material is not a substitute for reading the full 2012 Annual Report.
The information included in the Appendix is extracted from the 2012 Annual Report which was approved by the Directors on February 25, 2013.
Deputy Company Secretary
For further information please contact:
Eric Rojas ([email protected])
+1 781 482 0999
Sarah Elton-Farr ([email protected])
+44 1256 894 157
Notes to editors
Shire plc (the “Company”) and its subsidiaries (collectively “Shire” or the “Group”) develop and provide healthcare in the areas of:
- Behavioral Health and Gastro Intestinal conditions;
- Rare Genetic Diseases; and
- Regenerative Medicine;
as well as other symptomatic conditions treated by specialist physicians. To serve different patient groups, Shire operates in three distinct business units: Specialty Pharmaceuticals (“SP”), Human Genetic Therapies (“HGT”) and Regenerative Medicine (“RM”).
For further information about Shire, please visit our website: www.shire.com.
The “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that:
- Shire’s products may not be a commercial success;
- revenues from ADDERALL XR® are subject to generic erosion;
- the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payors in a timely manner for Shire's products may impact future revenues and earnings;
- Shire relies on a single source for manufacture of certain of its products and a disruption to the supply chain for those products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis;
- Shire uses third party manufacturers to manufacture many of its products and is reliant upon third party contractors for certain goods and services, and any inability of these third party manufacturers to manufacture products, or any failure of these third party contractors to provide these goods and services, in each case in accordance with its respective contractual obligations, could adversely affect Shire’s ability to manage its manufacturing processes or to operate its business;
- the development, approval and manufacturing of Shire’s products is subject to extensive oversight by various regulatory agencies and regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
- the actions of certain customers could affect Shire's ability to sell or market products profitably and fluctuations in buying or distribution patterns by such customers could adversely impact Shire’s revenues, financial conditions or results of operations;
- investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire’s activities in the highly regulated markets in which it operates may result in the distraction of senior management, significant legal costs and the payment of substantial compensation or fines;
- adverse outcomes in legal matters and other disputes, including Shire’s ability to obtain, maintain, enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on Shire’s revenues, financial condition or results of operations;
and other risks and uncertainties detailed from time to time in Shire’s filings with the Securities and Exchange Commission, including those risks outlined on pages 26 to 32 of the full release.
Click here for the PDF version of this press release.